TPD52抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Raji cells, 231 cells, 293T cells, A549 cells, Primary antibody: P05438(TPD52 Antibody) at dilution 1/320, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

The tumor protein D52 (TPD52) is a member of the D52-like protein family, initially identified through its overexpression in breast cancer. Encoded by the *TPD52* gene on human chromosome 8q21. this small, coiled-coil motif-containing protein regulates diverse cellular processes, including cell proliferation, apoptosis, vesicular trafficking, and lipid metabolism. TPD52 interacts with signaling pathways like PI3K/AKT and MAPK, and its dysregulation is implicated in cancer progression, metastasis, and therapeutic resistance. Elevated TPD52 expression has been observed in multiple cancers, such as prostate, ovarian, and colorectal cancers, correlating with poor prognosis.

TPD52 antibodies are immunological tools designed to detect and quantify TPD52 protein levels in research and diagnostic contexts. Polyclonal and monoclonal variants are used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study TPD52's spatial expression, post-translational modifications, and interactions in cellular or tissue samples. These antibodies aid in exploring TPD52's role as a potential oncogenic driver or biomarker. Recent studies also investigate its utility in liquid biopsies for cancer monitoring. Commercially available TPD52 antibodies vary in specificity, with validation often performed using knockout cell lines or siRNA-mediated knockdown. Ongoing research focuses on leveraging TPD52-targeting antibodies for therapeutic applications, including antibody-drug conjugates or blocking tumor-stroma crosstalk.